Formulation And Evaluation Of Transdermal Patch For Polycystic Ovary Syndrome PCOS

Transdermal drug delivery has made an important contribution to medical practice. It is a medicated patch that delivers a specific amount of medication through the skin into the blood stream. An advantage of a transdermal drug delivery route over other types of medication delivery is that the patch provides a controlled release of the medication into the patient, usually through either a porous membrane covering a reservoir of medication or through body heat melting thin layers of medication embedded in the adhesive. The present investigation was aimed to formulate transdermal films of Spironolactone and Metformin HCL, which can be used for the treatment prevailing symptoms of PCOS using Solvent evaporation method and evaluated for physicochemical parameters like thickness, weight variation, moisture uptake, moisture content, folding endurance, and drug content values. Polycystic ovary syndrome (PCOS) is currently the leading cause of menstrual complications in women. It is characterized by clinical and/or biochemical hyperandrogenism, ovulation abnormalities and the presence of enlarged and/or polycystic ovaries in ultrasound images. It is often comorbid with hyperinsulinemia, dyslipidemia, overweight or obesity, and is a risk factor for the development of diabetes. Nine transdermal patches were prepared using different concentrations of Hydrooxypropyl methyl cellulose K4M (HPMC K4M) and Ethyl cellulose as polymers and Polyethylene glycol (PEG) as plasticizer. It was concluded that as the concentration of Plasticizer increases the folding endurance increases and as the concentration of Polymer increases thickness of patch and weight uniformity increases. Percentage moisture content and percentage moisture uptake decreases with increase in polymer concentration.